PharmaLogic agrees to acquire Lantheus radiopharmaceutical CDMO business and New Jersey manufacturing facility

PharmaLogic has signed a definitive agreement to acquire Lantheus' radiopharmaceutical CDMO operations and Springfield manufacturing facility, expanding specialist production capabilities for therapeutic radiopharmaceuticals.

PharmaLogic announced on 9 November 2026 that it had entered into a definitive agreement to acquire Lantheus' contract development and manufacturing operations together with its Springfield, New Jersey radiopharmaceutical manufacturing facility, with financial consideration undisclosed and completion still pending.

The planned acquisition would expand PharmaLogic's therapeutic radiopharmaceutical manufacturing capacity and integrate the acquired operations into its Agilera business to support a transatlantic CDMO platform for radioligand therapies, while remaining separate from Curium's pending acquisition of Lantheus and involving no newly announced regulatory approval.

Field	Content
Article Type	Deals
Acquirer	PharmaLogic
Seller	Lantheus
Deal Type	Definitive asset and manufacturing business acquisition agreement
Announcement Date	9 November 2026
Transaction Status	Agreed; completion pending
Acquired Business	Radiopharmaceutical contract development and manufacturing operations
Acquired Facility	Springfield radiopharmaceutical manufacturing facility
Facility Location	Springfield, New Jersey, United States
Industry Segment	Radiopharmaceutical manufacturing
Manufacturing Service Category	Contract development and manufacturing organisation
Service Category Abbreviation	CDMO
Therapeutic Focus	Therapeutic radiopharmaceuticals
Related Treatment Modality	Radioligand therapy
Receiving Business	Agilera
Planned Integration	Integration into PharmaLogic's Agilera business
Geographic Platform Objective	Transatlantic CDMO operations
Strategic Objective	Expand specialist radiopharmaceutical manufacturing capacity
Purchase Price	Not disclosed
Upfront Consideration	Not disclosed
Contingent Consideration	Not disclosed
Closing Date	Not specified in supplied summary
Regulatory Approval Announced	No
Related Corporate Transaction	Curium's pending acquisition of Lantheus
Relationship to Curium Transaction	Separate transaction
What Happened	PharmaLogic signed a definitive agreement to acquire Lantheus' radiopharmaceutical CDMO operations and New Jersey manufacturing facility.
Why It Matters	The transaction could increase specialist manufacturing capacity needed to support the growing radiopharmaceutical and radioligand therapy sector.
Strategic Significance	Strengthens PharmaLogic's manufacturing platform and broadens Agilera's potential service capabilities.
Industry Significance	Illustrates consolidation of specialised pharmaceutical manufacturing infrastructure supporting nuclear medicine therapies.
Transaction Clarification	The acquisition is agreed but has not been reported as completed.
Financial Clarification	The purchase consideration has not been disclosed and should not be inferred from other Lantheus transactions.
Key Takeaway	PharmaLogic plans to add Lantheus' CDMO operations and Springfield facility to its radiopharmaceutical manufacturing platform.
What to Watch	Transaction completion, facility integration, manufacturing capacity expansion and future radioligand therapy CDMO contracts.
Primary Source	PharmaLogic announcement
Primary Source URL	https://www.prnewswire.com/news-releases/pharmalogic-to-acquire-lantheus-cdmo-business-and-springfield-new-jersey-manufacturing-facility-302933626.html
Submitted Source	Fierce Pharma
Submitted Source URL	https://www.fiercepharma.com/pharma/radiopharma-player-pharmalogic-snaps-lantheus-cdmo-business-plant-curium-acquisition
Relevant Date	9 November 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com